Physician profile
Robert B Levy
NPI 1760582654
$6,638.87
in general payments reported to CMS, 2019-2025
31 companies · $1,128 in 2025
The $1,128 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $342 · 2021: $604 · 2022: $1,114 · 2023: $1,151 · 2024: $1,229 · 2025: $1,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,175.47 | 2019-2025 | |
| Janssen Biotech, INC. | $1,163.73 | 2019-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $459.00 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $411.96 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.88 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $230.90 | 2019-2025 | |
| Ardelyx, INC. | $189.76 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $186.62 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $178.47 | 2021-2024 | Linzess |
| Celgene Corporation | $174.72 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $165.50 | 2021-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $152.02 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $101.07 | 2021-2023 | |
| Qol Medical, LLC | $83.11 | 2022 | |
| Phathom Pharmaceuticals, INC. | $77.77 | 2024-2025 | Voquezna |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $64.51 | 2024 | Resmetirom |
| Exact Sciences Corporation | $63.19 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $62.21 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $53.01 | 2022-2023 | Injectafer |
| Amgen INC. | $44.34 | 2023 | Amjevita, Avsola |
| Regeneron Healthcare Solutions, INC. | $37.95 | 2022-2024 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $31.83 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.41 | 2023 | Onpattro |
| Allergan, INC. | $23.11 | 2019 | |
| Fresenius Kabi USA, LLC | $23.02 | 2023 | Idacio |
| Intercept Pharmaceuticals, INC. | $21.97 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.59 | 2024 | Bylvay |
| Celltrion USA INC. | $20.49 | 2025 | Vegzelma |
| Boston Scientific Corporation | $18.87 | 2019 | |
| Alfasigma USA, INC. | $15.90 | 2022 | |
| Echosens North America, INC. | $10.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.